To assess the outcome of extremely low birth weight (ELBW) infants r1000 g as it relates to antenatal steroids (ANS) therapy.
INTRODUCTION
Despite marked improvements in perinatal care, complications of preterm birth, notably respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), and chronic lung disease (CLD), persist. Moreover, RDS remains a prominent cause of infant mortality. 1 To improve the outcome of preterm infants, and in particular reduce the incidence and severity of RDS, the National Institute of Health issued a consensus statement in 1994, which recommended the use of antenatal steroids (ANS) for mothers in preterm labor with fetuses of estimated gestational age between 24 and 34 weeks. 2 This consensus statement was largely based on a meta-analysis of prior ANS trials in which a 50% reduction in the incidence of RDS following ANS exposure was reported. 3 However, no significant effect on RDS was noted in a limited subgroup analysis of very low birth weight (VLBW) infants <28 weeks gestational age (GA). 4 The current dosing of ANS which totals 24 mg of either dexamethasone (four doses) or betamethasone (two doses) is based on animal studies, 5, 6 and it remains unclear whether this represents the optimal dose for VLBW infants. At our institution, dexamethasone is administered to mothers who are in preterm labor with fetuses between 24 and 34 weeks estimated GA, unless there is evidence of hypertension including pregnancyinduced hypertension, diabetes mellitus, clinical chorioamnionitis, cervical dilation Z5 cm or evidence of abruptio placenta. During the period of this study, the standard of care consisted of repeating the steroid course every week up to delivery.
It has become evident that a substantial number of mothers who are potential candidates for ANS are not treated or receive partial dexamethasone treatment (less than four doses), because of late presentation and/or imminent delivery upon arrival to the delivery suite. It remains unclear whether the outcome of VLBW infants, and in particular those extremely low birth weight (ELBW) infants r1000 g, is influenced by a partial as compared to a full course of ANS. The objective of this retrospective cohort analysis is to assess the outcome of ELBW infants r1000 g as it relates to ANS therapy.
METHODS
The patient population comprises all live-born ELBW infants r1000 g who were delivered and resuscitated at Parkland Memorial Hospital (PMH) between January 1995 and December 1997. Infants of mothers with pregnancy-induced hypertension (PIH) and diabetes were excluded from the analysis because they are not candidates for ANS at our institution. 7 In addition, infants with congenital and chromosomal anomalies, discordant twin sets (>20% discordance in weight) and those with severe growth restriction were excluded because they represent a subset of patients with increased morbidity. Severe growth restriction was defined as a birth weight less than the fifth percentile of birth weight for gestational age. 8 The predictor variable for this analysis is the number of ANS doses received prior to delivery. The outcome parameters include: (1) hyaline membrane disease (HMD), defined as respiratory distress with increasing oxygen requirement and diagnostic radiographic findings, and in the absence of other causes of respiratory distress; (2) rescue surfactant treatment, administered to ventilated infants with HMD and an oxygen requirement >30% (prophylactic surfactant is not used at our institution); (3) CLD defined as an oxygen requirement at 36 weeks postmenstrual age in surviving infants; (4) number of intubation days; (5) incidence of symptomatic patent ductus arteriosus (PDA), defined on clinical criteria and an abnormal echocardiogram; (6) postnatal steroids use for CLD; (7) total and severe IVH (grade 3±intraparenchymal involvement); 9 (8) death defined as death prior to hospital discharge; and (9) CLD or death as a combined outcome. In addition, we collected information on infants' birth weight, gestational age, gender, race, mode of delivery, 5 minutes Apgar score, number of twin births, and evidence of chorioamnionitis or placental abruption. Chorioamnionitis was a clinical diagnosis based on the following: maternal fever Z381C not explained by another source of infection, fetal tachycardia, uterine tenderness, and foul odor upon delivery of the infant. 10 During the study period, the criteria for emergent C-section included infants Z25 weeks GA with fetal heart rate decelerations, and/or progressive labor (>5 cm cervical dilation) with noncephalic presentation; also, ampicillin for group B streptococci (GBS) was administered to mothers of all preterm infants. 7, 11 Statistical Analysis In the first set of analyses, study infants were divided into three groups based on ANS exposure as follows: no dose (none), one to two doses (partial course), and three to four doses (complete course). These groups were compared with regard to the outcome parameters. One-way analysis of variance (ANOVA) or one-way ANOVA for ranks were used for continuous data when normality failed, and w 2 analysis with adjusted multiple comparisons for proportions was used for categorical data. 12 All values are presented as the mean±SD unless otherwise indicated.
To adjust for the effects of birth weight, gestational age, race, gender, mode of delivery, and clinical chorioamnionitis and to examine the additive effect of each ANS dose on ELBW infants' outcome, six separate logistic models were constructed for each of HMD, surfactant use, PDA, IVH, death, and combined CLD and death. In each logistic model, orthogonal effects coding was used to compare the four levels of ANS dose (none, 1, 2, and 3 or 4) comparing no (or none) ANS dose to each of the higher level doses. Three to four doses were grouped together because only four infants received three doses and four infants received eight doses of ANS prior to delivery. Seven patients were excluded from the IVH logistic model secondary to missing data due to early death. SAS V8.0 software package was used in all analysis. All tests are twotailed with Type I error set at 5%. All logistic regression models are well fit based on the Hosmer -Lemeshow test. The model with death as the outcome variable was not well fit and is not included in the results.
RESULTS

General
In all, 171 infants were born and resuscitated at PMH during the study period. A total of 47 patients were excluded due to maternal PIH, diabetes mellitus, severe growth restriction, chromosomal and/or congenital anomalies, and discordant twin sets. The data from 124 infants who were eligible for ANS were analyzed. Of the 124 eligible infants, 47 (38%) received no steroids, 31 (25%) received a partial course (one to two doses), and 46 (37%) received a complete course of ANS (three to four doses).
The demographic characteristics of the infants according to the three steroids dosing groups (none, partial, and complete) are summarized in Table 1 . In the complete group (n ¼ 46), four infants received a total of eight doses (two courses) and four infants received three doses of ANS. In the partial group, 11 infants received two doses, while 20 received only one dose of ANS. Among the three groups, there were no differences in birth weight, gestational age, gender or race distribution, arterial cord pH, number of twin gestations, chorioamnionitis, and abruptio placentae. However, infants who received no ANS were more likely to be delivered via emergent C-section ( p ¼ 0.006), and exhibit a lower 5 minutes Apgar ( p ¼ 0.02) compared to the partial and complete ANS groups. The effects of ANS dosing on the clinical outcome parameters are summarized in Table 2 . Infants with no ANS exposure were more likely to exhibit HMD, receive surfactant replacement therapy, develop PDA, IVH (including severe IVH), and more likely to die as compared to infants with complete exposure to ANS. The combined outcome of CLD or death was also significantly decreased after a complete ANS course. There were no significant differences between the no exposure and the partial exposure group with regard to any of the above outcomes, but there was a trend towards less morbidity in the partial ANS group. Surfactant use and total IVH were significantly less in the complete versus the partial group. No differences were noted among the three groups with regard to CLD, postnatal steroids therapy for ventilator-dependent infants, or the number of intubated days in surviving infants. Table 3 summarizes the results of the logistic models. Except for the outcome of PDA and CLD or death, the logistic model results are consistent with the univariate findings. After correcting for birth weight, gestational age, gender, race, mode of delivery, and clinical chorioamnionitis, two doses and three to four doses of ANS were associated with a significant decrease in the occurrence of HMD as compared to no ANS; the odds ratios (OR) and 95% confidence intervals were 0.1 (0.0 to 0.7) and 0.2 (0.1 to 0.5), respectively. However, with a single dose of ANS, the incidence of HMD was not different from those infants with no ANS exposure. Only a complete course (three to four doses) of ANS was associated with a significant decrease in the use of surfactant, OR 0.2 (0.1 to 0.5). Also, IVH was significantly reduced only after a complete course of ANS, OR 0.2 (0.0 to 0.5). CLD and death were significantly reduced after two doses of ANS, OR 0.2 (0.0 to 0.9) and approached significance for the three to four dose, 0.4 (0.1 to 1.1). The incidence of PDA in the logistic model decreased after two doses of ANS, and approached significance in the complete versus no ANS comparison, OR 0.4 (0.2 to 1.1).
Logistic Model
All univariate and logistic model results were unchanged when the four infants with eight doses (two courses) of ANS were excluded from the analysis.
DISCUSSION
The data in this report demonstrate a significant decrease in the incidence of HMD, the need for surfactant replacement therapy as well as a decrease in symptomatic PDA, total and severe IVH, death and CLD or death in ELBW infants r1000 g following exposure to ANS, findings consistent with prior reports. 4,13 -16 These beneficial effects of ANS were dose dependent, which is the novel and important observation of this report. Specifically, an effect on HMD was noted after the second dose of ANS, whereas a complete course This table summarizes the results of five separate logistic models, one for each outcome. Correction for the effect of BW, GA, gender, race, mode of delivery, and clinical chorioamnionitis is performed for each model. The three to four ANS dose group includes the four infants with three and the four infants with eight doses. *Data from seven infants not included secondary to early death.
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Antenatal Steroids Treatment and Extremely Low Birth Weight Infants was needed for an effect on IVH, and death. However, there was no effect of any ANS exposure on the occurrence of CLD, the number of intubation days, or the use of postnatal steroids therapy to prevent CLD. The effect of ANS on early pulmonary function is consistent with experimental data. 17, 18 Thus, Ikegami et al. 17 reported in a fetal lamb model, that 15 hours of betamethasone exposure resulted in a two-fold improvement in lung compliance and volume, and a four-to five-fold decrease in lung edema. 17 Ballard et al. demonstrated in preterm sheep that exposure to one dose of betamethasone 48 hours prior to delivery increased the maximum lung volume and dynamic compliance, as well as decreased capillary alveolar permeability when compared to controls. 18 Interestingly, in that report, pulmonary saturated phosphatidylcholine and surfactant protein B levels in pulmonary lavage fluid were not affected. 18 It is likely that the dose-dependent decrease in surfactant use noted in this report reflects improved lung compliance in addition to increased pulmonary surfactant formation.
Previous reports have demonstrated a reduction in the incidence of total as well as severe IVH following exposure to ANS. 4, 14, 16 The data in this report indicate that this effect is dose dependent, and only seen after a full course of ANS although there was a trend for less severe IVH in infants who received any ANS exposure ( Table 2) . The potential mechanism(s) that might account for this neuroprotective effect include improved pulmonary function, more stable arterial blood pressure, and enhanced maturation of the germinal matrix. [19] [20] [21] Consistent with previous reports, 22 a beneficial effect of ANS on symptomatic PDA was noted in our cohort of ELBW infants. The reduced incidence of symptomatic PDA suggests a steroid effect on the ductus. Postulated mechanism(s) includes interference with prostaglandin synthesis, a reduction in sensitivity of the ductal muscle to prostaglandin E 2 (PGE 2 ) and an increase in the activity of PGE 2 inactivation enzyme. 23, 24 Approximately 50% of eligible infants either did not receive ANS, or received only one dose immediately prior to delivery. The reasons for the failure to administer ANS to eligible mothers are not obvious from this retrospective analysis. However, a partial explanation for this finding may be deduced from the observation that approximately 25% of infants not exposed to ANS were delivered via emergent C-section. This was significantly more common than that observed in the two ANS groups (Table 1) . We did not attempt to delineate the specific causes resulting in an emergent delivery; however, it is usually secondary to preterm labor with signs of fetal distress, or in imminent deliveries with noncephalic presentation. In view of the decrease in HMD, PDA, and IVH associated with a complete course of ANS, the opportunity to administer a full course to all eligible women may be enhanced by efforts of early detection and/or prevention of preterm labor. [25] [26] [27] This is of particular importance given the lower mortality independent of or when coupled with CLD in infants who received two or more doses of ANS (Tables 2 and 3 ). However, efforts to prevent preterm labor have to be balanced against the risk for infection, especially with the evidence supporting its role in precipitating preterm labor. 27 Indeed, clinical chorioamnionitis was more common in mothers who had received a complete ANS course as compared to those mothers with a partial course or no ANS exposure (Table 1) .
Chorioamnionitis has been linked to increased neonatal morbidity in VLBW infants. 9, 28 In particular, it is associated with an increased risk for CLD. 28 Interestingly, in this report, although the incidence of HMD was reduced, ANS had no effect on the development of CLD; a finding consistent with the meta-analysis of Crowley.
5 This is not a surprising finding, since the pathophysiology of CLD appears to be multifactorial including baro and/ or volutrauma, continuous oxidant stress, inflammation, and the inability of the premature lung to regenerate the epithelial airway lining. 29 Thus, as has been noted with surfactant administration studies, ANS while improving early pulmonary function is not specific enough to prevent the ongoing postnatal injury in the premature lung. Additional analysis was performed excluding infants born to mothers with clinical chorioamnionitis (data not shown), and did not alter the outcome regarding IVH, HMD, CLD, and CLD or death. However, this important question can only be appropriately addressed in a prospective study.
In conclusion, the data suggest an additive effect of each dose of ANS therapy on the prevention of HMD, PDA, and IVH, important predictors of neonatal mortality and morbidity. Whether this beneficial effect of ANS is due to the amount of steroids given to the infant's mother or to the duration of fetal exposure cannot be answered from this retrospective analysis. Importantly, almost half of eligible mothers received limited or no ANS. It is likely that some of the mechanisms resulting in imminent delivery, and the inability to administer ANS, notably fetal distress, may in itself increase the inherent risk for both respiratory and neurologic morbidity. Thus, those ELBW infants not exposed to ANS provide an opportunity to target a subpopulation, who might derive the greatest benefit from postnatal interventions to decrease mortality and morbidity.
